Dual‐Responsive Drug‐Delivery System Based on PEG‐Functionalized Pillararenes Containing Disulfide and Amido Bonds for Cancer Theranostics

Xia, Jiachen; Wang, Jian; Zhao, Qin; Lu, Bing; Yao, Yong

doi:10.1002/cbic.202300513

Cited by 4 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,27 Among them, dynamic covalent bonds such as borate ester bonds, 28 hydrazone bonds, and disulfide bonds have been used in antitumor nanomedicine research because of their ability to break through the tumor microenvironment. 29,30 Boric acid can be quickly esterified with diol groups in water to form borate ester bonds, which can be effectively broken under acidic conditions. 31 Notably, BE has a dihydroxy group that can be esterified with phenylboric acid or phenylboric acid derivatives, such as 3-aminophenyl boric acid, to form a borate ester bond.…”

Section: Introductionmentioning

confidence: 99%

Preparation of Biomimetic Selenium–Baicalein Nanoparticles and Their Targeted Therapeutic Application in Nonsmall Cell Lung Cancer

Shi,

Wang,

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

In this study, we prepared bionic selenium–baicalein nanoparticles (ACM-SSe–BE) for the targeted treatment of nonsmall cell lung cancer. Due to the coating of the A549 membrane, the system has homologous targeting capabilities, allowing for the preparation of target tumor cells. The borate ester bond between selenium nanoparticles (SSe) and baicalein (BE) is pH-sensitive and can break under acidic conditions in the tumor microenvironment to achieve the targeted release of BE at the tumor site. Moreover, SSe further enhances the antitumor effect of BE by increasing the production of ROS in tumor cells. Transmission electron microscopy (TEM) images and dynamic light scattering (DLS) showed that the ACM-SSe–BE had a particle size of approximately 155 ± 2 nm. FTIR verified the successful coupling of SSe and BE. In vitro release experiments indicated that the cumulative release of ACM-SSe–BE at pH 5.5 after 24 h was 69.39 ± 1.07%, which was less than the 20% release at pH 7.4, confirming the pH-sensitive release of BE in ACM-SSe–BE. Cell uptake experiments and in vivo imaging showed that ACM-SSe–BE had good targeting ability. The results of MTT, flow cytometry, Western blot, and cell immunofluorescence staining demonstrated that ACM-SSe–BE promoted A549 cell apoptosis and inhibited cell proliferation. The in vivo antitumor results were consistent with those of the cell experiments. These results clearly suggested that ACM-SSe–BE will be a promising bionic nanosystem for the treatment of nonsmall cell lung cancer.

show abstract